Live Quote · NASDAQFRESHealthcare · Biotechnology

Fresh2 Group Limited

$0.85▼ 23.42%($-0.26)

TickerSpark Score

44/100

▌ Weak

60

Valuation

40

Profitability

55

Growth

36

Health

30

Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FRES research report →

52-Week Range1% of range

Low

$0.73

Current

$0.85

High

$9.00

Company Overviewfresh2.co

About the company

Fresh2 Group Limited, a biotechnology company established in New York, New York, in 2010, officially adopted its current name in April 2023, having previously been known as AnPac Bio-Medical Science Co. , Ltd. The company is primarily engaged in the research, development, promotion, and sale of advanced multi-cancer screening and detection tests within the People's Republic of China, leveraging its proprietary cancer differentiation analysis (CDA) technology and associated devices for corporate and life insurance clients.

CEO: Haohan Xu
IPO: 2020
Employees: 75
HQ: New York City, NY, US

Price Chart

-78.75% · this period

Valuation

Market Cap: $2.08M
P/E: -0.00
P/S: 1.17
P/B: -0.00
EV/EBITDA: -0.25
Div Yield: 0.00%

Profitability

Gross Margin: 69.21%
Op Margin: -870.20%
Net Margin: -846.01%
ROE: 1121.57%
ROIC: -2573.82%

Growth & Income

Revenue: $12.04M · -33.04%
Net Income: $-101,893,000 · 14.16%
EPS: $-106578.00 · 69.06%
Op Income: $-104,807,000
FCF YoY: 24.16%

Performance & Tape

52W High: $9.00
52W Low: $0.73
50D MA: $1.06
200D MA: $2.29
Beta: 1.28
Avg Volume: 17.45K

Get TickerSpark's AI analysis on FRES

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

Date	Insider	Role	Type	Shares	Value
Jan 1, 24	Liang Zhijun	director:	other	0	—
Mar 11, 24	Zhao Zhigang	director	other	100,000	$0
Apr 14, 25	Li Xiaoyu	director, officer: Chief Financial Officer	other	471,695	$0
Mar 11, 24	Pu Tianruo	director	other	100,000	$0
Mar 11, 24	Tian Honggang	director	other	100,000	$0
Jan 1, 24	Xu Haohan	director, 10 percent owner, officer: Chief Executive Officer	other	0	—
Jan 1, 24	Xu Haohan	director, 10 percent owner, officer: Chief Executive Officer	other	0	—

Coverage · FRES

Our FRES coverage

Recent articles, reports, and earnings notes.

View all →

IPO

Sinda Ltd. IPO: What Investors Need to Know

Sinda Ltd. is expected to list on the NYSE on 2026-07-01 under the symbol SIND, with shares priced in a $11.25 to $13.25 range. The deal gives public-market investors a pure-play silver exploration story with no revenue yet, but meaningful resource potential in Mexico. The bull case is leverage to silver prices and a large resource base; the bear case is classic pre-production mining risk, including dilution, permitting, and the need for more capital.